Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00088556
Status:
COMPLETED
Last Update Posted:
2012-05-31
First Post:
2004-07-29
Brief Title:
Carboplatin Paclitaxel and TLK286 Telcyta as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
Sponsor:
Telik
Organization:
Telik
Study Overview
Official Title:
Phase 1-2a Dose-Ranging Study of the Triplet Combination of Carboplatin Paclitaxel and TLK286 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2011-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to study the efficacy and safety of the triplet combination of TLK286 carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None